In addition to contributing to decreased regulatory function, CD226 has been identified to contain a potential gain-of-function risk variant contributing to a propensity for multiple autoimmune diseases including T1D, SLE, rheumatoid arthritis (RA), and multiple sclerosis (MS) (32, 34–36). Here, CD226 is linked to type 1 diabetes mellitus.